The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
LEDAGA® (chlormethine gel) approved by the EMA for the treatment of MF-CTCL
On the 7th March 2017, the European Medicines Agency (EMA) granted marketing authorization to LEDAGA® (chlormethine gel, 160μg/g) to treat Mycosis Fungoides-type Cutaneous T-Cell Lymphoma (MF-CTCL).
The approval of Actelion’s LEDAGA® comes after a positive opinion that was given by the EMA’s Committee for Medicinal Products for Human Use (CHMP) last year, in December 2016. The positive opinion, and the subsequent approval, were based on results of the pivotal 201 study (NCT00168064), previously reported by the Lymphoma Hub.
LEDAGA® has already been approved by the U.S. Food and Drug Administration (FDA) in this indications, and is marketed as VALCHLOR®. A European launch of LEDAGA® is expected to take place after January 2018.
References